[go: up one dir, main page]

MX2016013884A - Metodo para fabricar suspensiones farmaceuticas liquidas que contienen bismuto. - Google Patents

Metodo para fabricar suspensiones farmaceuticas liquidas que contienen bismuto.

Info

Publication number
MX2016013884A
MX2016013884A MX2016013884A MX2016013884A MX2016013884A MX 2016013884 A MX2016013884 A MX 2016013884A MX 2016013884 A MX2016013884 A MX 2016013884A MX 2016013884 A MX2016013884 A MX 2016013884A MX 2016013884 A MX2016013884 A MX 2016013884A
Authority
MX
Mexico
Prior art keywords
liquid pharmaceutical
containing liquid
pharmaceutical suspensions
making bismuth
bismuth
Prior art date
Application number
MX2016013884A
Other languages
English (en)
Other versions
MX370908B (es
Inventor
Ray Gilbert Steven
Michael Tunis Adam
Paul Fitch V Edward
Ho Derrick
Jerome White Daniel Jr
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2016013884A publication Critical patent/MX2016013884A/es
Publication of MX370908B publication Critical patent/MX370908B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para producir una suspensión farmacéutica líquida mediante el mezclado de silicato de aluminio y magnesio, goma gelana, subsalicilato de bismuto y metilcelulosa.
MX2016013884A 2014-04-29 2015-04-29 Metodo para fabricar suspensiones farmaceuticas liquidas que contienen bismuto. MX370908B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461985653P 2014-04-29 2014-04-29
PCT/US2015/028215 WO2015168241A1 (en) 2014-04-29 2015-04-29 Method for making bismuth-containing liquid pharmaceutical suspensions

Publications (2)

Publication Number Publication Date
MX2016013884A true MX2016013884A (es) 2017-02-02
MX370908B MX370908B (es) 2020-01-08

Family

ID=53267574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013884A MX370908B (es) 2014-04-29 2015-04-29 Metodo para fabricar suspensiones farmaceuticas liquidas que contienen bismuto.

Country Status (10)

Country Link
US (3) US9486436B2 (es)
EP (1) EP3137059B1 (es)
CN (1) CN106255495B (es)
AU (1) AU2015253187B2 (es)
CA (2) CA3041501C (es)
ES (1) ES2682210T3 (es)
MX (1) MX370908B (es)
PL (1) PL3137059T3 (es)
RU (1) RU2694530C2 (es)
WO (1) WO2015168241A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3134080A1 (en) 2014-04-23 2017-03-01 The Procter & Gamble Company Cyclohexanecarboxamide with cooling properties
EP3137056B1 (en) * 2014-04-29 2020-12-02 The Procter and Gamble Company Bismuth-containing liquid pharmaceutical suspensions
AU2015253187B2 (en) * 2014-04-29 2017-10-05 The Procter & Gamble Company Method for making bismuth-containing liquid pharmaceutical suspensions
WO2017037706A1 (en) * 2015-08-31 2017-03-09 Zelikman Vadim An appartus for dispensing a predefined dosage form
WO2019040878A1 (en) 2017-08-25 2019-02-28 L. Perrigo Company PHARMACEUTICAL SUSPENSIONS FOR BISMUTH SUBSALICYLATES
FR3089392B1 (fr) * 2018-12-07 2021-12-31 Oenotropic Innovation Utilisation d’un polysaccharide et d’un compose soufre pour la mise en suspension de particules dans une composition liquide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL32020A (en) 1968-04-18 1972-11-28 Brown G Antacid compositions
US4801454A (en) * 1986-07-17 1989-01-31 The Proctor & Gamble Company Processes for making colored pharmaceutical compositions
US5013560A (en) * 1989-03-17 1991-05-07 The Procter & Gamble Company Microbially-stable bismuth-containing liquid pharmaceutical suspensions
US20010016577A1 (en) * 1998-08-24 2001-08-23 Douglas Joseph Dobrozsi Oral mucoadhesive compositions containing gastrointestinal actives
US6482865B1 (en) 2000-04-12 2002-11-19 Gastropal Partners Method for preparing colloidal solution of bismuth sodium tartrate
US6712496B2 (en) 2001-07-26 2004-03-30 The Procter & Gamble Company Auger fed mixer apparatus and method of using
AU2003210812A1 (en) * 2002-02-04 2003-09-02 Pharmacia Corporation Stable pharmaceutical composition useful for treating gastrointestinal disorders
CA2477964A1 (en) 2002-03-04 2003-09-12 Medrx Co., Ltd. Liquid matrix transforming its phase in living body and oral liquid preparation
GB0507167D0 (en) * 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
WO2007111888A1 (en) 2006-03-22 2007-10-04 The Procter & Gamble Company Liquid treatment unitized dose composition
US20080008814A1 (en) * 2006-06-22 2008-01-10 Philip Henry Jackson Acidified Protein Beverages Containing Suspended Particulates and Methods of Making Same
US20080227892A1 (en) 2007-03-13 2008-09-18 Van Der Wielen Maarten Paint formulations comprising cellulose ether/network building polymer fluid gel thickeners
CA2794102C (en) * 2007-06-28 2014-08-19 The Procter & Gamble Company Apparatus and method for mixing by producing shear and/or cavitation, and components for apparatus
US8394752B2 (en) 2008-12-18 2013-03-12 The Procter & Gamble Company Pearlescent agent slurry for liquid treatment composition
AU2015253187B2 (en) * 2014-04-29 2017-10-05 The Procter & Gamble Company Method for making bismuth-containing liquid pharmaceutical suspensions
EP3137056B1 (en) * 2014-04-29 2020-12-02 The Procter and Gamble Company Bismuth-containing liquid pharmaceutical suspensions

Also Published As

Publication number Publication date
ES2682210T3 (es) 2018-09-19
BR112016025072A2 (pt) 2017-08-15
US20170027964A1 (en) 2017-02-02
RU2694530C2 (ru) 2019-07-16
US9486436B2 (en) 2016-11-08
EP3137059B1 (en) 2018-05-23
AU2015253187A1 (en) 2016-10-13
CA2943420A1 (en) 2015-11-05
WO2015168241A1 (en) 2015-11-05
US20150306061A1 (en) 2015-10-29
PL3137059T3 (pl) 2018-10-31
US10034888B2 (en) 2018-07-31
CN106255495B (zh) 2019-10-22
BR112016025072A8 (pt) 2021-07-06
CA3041501A1 (en) 2015-11-05
US20180303852A1 (en) 2018-10-25
CA3041501C (en) 2020-09-22
US10532063B2 (en) 2020-01-14
RU2016137537A3 (es) 2018-05-29
CN106255495A (zh) 2016-12-21
MX370908B (es) 2020-01-08
EP3137059A1 (en) 2017-03-08
CA2943420C (en) 2019-06-25
AU2015253187B2 (en) 2017-10-05
RU2016137537A (ru) 2018-05-29

Similar Documents

Publication Publication Date Title
EP3109225A4 (en) Method for purifying fluid that includes trifluoroethylene, and method for producing trifluoroethylene
MX2016013884A (es) Metodo para fabricar suspensiones farmaceuticas liquidas que contienen bismuto.
PT3137679T (pt) Método para produzir uma suspensão de celulose microfibrilada, celulose microfibrilada e a sua utilização
HUE037981T2 (hu) Eljárás 5-hidroximetilfurfural szelektív oxidálására
EP3173437A4 (en) Method for producing porous cellulose medium
EP3330223A4 (en) Method for producing silica sol
EP3109178A4 (en) Resin-coated metal plate for container and production method therefor
EP3175916A4 (en) Method for producing core-shell catalyst
SG11201700910QA (en) Suspension of a magnesium silicate, method for making same and use thereof as a phosphor
EP3106223A4 (en) Method for producing core-shell catalyst particles
EP3168022A4 (en) Production method for plate-integrated gasket
PL3122808T3 (pl) Sposób wytwarzania porowatych materiałów
WO2015169738A3 (de) Verfahren und vorrichtung zur strukturweisen herstellung eines hydridspeichers mit einem 3d-drucker
PT3368199T (pt) Misturador de alta concentração para a produção de uma suspensão de celulose com elevada concentração de celulose
EP3279219A4 (en) Method for producing porous cellulose medium
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
SG11201801939SA (en) Method for manufacturing platelets by rotary stirring culture method
PL3160985T3 (pl) Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylo-l-fenyloalaninoamidu
EP3150552A4 (en) Method for producing carbon particles by detonation
EP3133680A4 (en) Method for producing electrode
FR3030348B1 (fr) Procede pour l'assemblage d'une ebauche de pneumatique
MA40447A (fr) Composition pharmaceutique orale d'isotrétinoïne
EP3182981A4 (en) Process for the production of isomaltooligosaccharides
MX2016015465A (es) Composicion farmaceutica oral de isotretinoina.
EP3127943A4 (en) Process for producing nanoparticles

Legal Events

Date Code Title Description
FG Grant or registration